| Developing human laboratory models of smoking lapse behavior for medication screening. | |
| | |
MedLine Citation:
|
PMID: 18855800 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Use of human laboratory analogues of smoking behavior can provide an efficient, cost-effective mechanistic evaluation of a medication signal on smoking behavior, with the result of facilitating translational work in medications development. Although a number of human laboratory models exist to investigate various aspects of smoking behavior and nicotine dependence phenomena, none have yet modeled smoking lapse behavior. The first instance of smoking during a quit attempt (i.e. smoking lapse) is highly predictive of relapse and represents an important target for medications development. Focusing on an abstinence outcome is critical for medication screening as the US Food and Drug Administration approval for cessation medications is contingent on demonstrating effects on smoking abstinence. This paper outlines a three-stage process for the development of a smoking lapse model for the purpose of medication screening. The smoking lapse paradigm models two critical features of lapse behavior: the ability to resist the first cigarette and subsequent ad libitum smoking. Within the context of the model, smokers are first exposed to known precipitants of smoking relapse (e.g. nicotine deprivation, alcohol, stress), and then presented their preferred brand of cigarettes. Their ability to resist smoking is then modeled and once smokers 'give in' and decide to smoke, they participate in a tobacco self-administration session. Ongoing and completed work developing and validating these models for the purpose of medication screening is discussed. |
| | |
Authors:
|
Sherry A McKee |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2008-10-09 |
Journal Detail:
|
Title: Addiction biology Volume: 14 ISSN: 1369-1600 ISO Abbreviation: Addict Biol Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-12 Completed Date: 2009-04-23 Revised Date: 2011-05-02 |
Medline Journal Info:
|
Nlm Unique ID: 9604935 Medline TA: Addict Biol Country: England |
Other Details:
|
Languages: eng Pagination: 99-107 Citation Subset: IM |
Affiliation:
|
Yale University School of Medicine, New Haven, CT 06519, USA. mckee@yale.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alcohol Drinking
/
psychology Arousal Bupropion / therapeutic use Cues Drug Evaluation, Preclinical Humans Models, Psychological* Motivation Naltrexone / therapeutic use Nicotine / therapeutic use Psychotropic Drugs / therapeutic use* Recurrence / prevention & control Smoking / prevention & control, psychology* Smoking Cessation / psychology* Social Environment* Social Facilitation Tobacco Use Disorder / psychology*, rehabilitation* |
| Grant Support | |
ID/Acronym/Agency:
|
M01 RR000125-411079/RR/NCRR NIH HHS; M01 RR000125-41S11079/RR/NCRR NIH HHS; P50 AA015632-060003/AA/NIAAA NIH HHS; P50 AA015632-070003/AA/NIAAA NIH HHS; P50 AA015632-080003/AA/NIAAA NIH HHS; P50 AA015632-090003/AA/NIAAA NIH HHS; P50 AA015632-100003/AA/NIAAA NIH HHS; P50AA015632/AA/NIAAA NIH HHS; PL1 DA024859-02/DA/NIDA NIH HHS; R21DA017234/DA/NIDA NIH HHS; RL1 DA024857-01/DA/NIDA NIH HHS; RL1 DA024857-02/DA/NIDA NIH HHS; RL1 DA024857-03/DA/NIDA NIH HHS; RL1DA024857/DA/NIDA NIH HHS; UL1-RR024925/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Psychotropic Drugs; 16590-41-3/Naltrexone; 34841-39-9/Bupropion; 54-11-5/Nicotine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identifying the neural circuitry of alcohol craving and relapse vulnerability.
Next Document: Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of ...